Design of Antimalarial Pharmacokinetic Studies

Grant number: 566855 | Funding period: 2009 - 2012

Completed

Abstract

Each year there are more than 500 million episodes of malaria and over a million deaths. One of the main causes of this burden is inadequate treatment of young children and pregnant women. This project will improve research methods for determining effective treatment for all malaria patients, which in turn, will improve cure rates and slow the emergence and spread of drug resistance.

Related publications (4)

A robust design for identification of the Parasite Clearance Estimator

KM Jamsen, SB Duffull, J Tarning, RN Price, JA Simpson

2013-11-18

Background: Anti-malarial efficacy needs to be monitored continually to ensure optimal dosing in the face of emerging anti-malaria..

Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria

KM Jamsen, SB Duffull, J Tarning, N Lindegardh, NJ White, JA Simpson

2012-05-03

Background: Artemisinin-based combination therapy (ACT) is currently recommended as first-line treatment for uncomplicated malaria..

Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria

KM Jamsen, SB Duffull, J Tarning, N Lindegardh, N White, JA Simpson

2011-07-05

Background: Currently, population pharmacokinetic (PK) studies of anti-malarial drugs are designed primarily by the logistical and..

Towards optimal design of anti-malarial pharmacokinetic studies

JA Simpson, KM Jamsen, RN Price, NJ White, N Lindegardh, J Tarning, SB Duffull

2009-09-04

Background. Characterization of anti-malarial drug concentration profiles is necessary to optimize dosing, and thereby optimize cu..

University of Melbourne Researchers

Julie Simpson